Navigation Links
Cardioxyl Pharmaceuticals Presents Data On Its Clinical Candidate, CXL-1020, at the 60th Annual American College of Cardiology Scientific Session
Date:4/4/2011

NEW ORLEANS and CHAPEL HILL, N.C., April 4, 2011 /PRNewswire/ -- Cardioxyl Pharmaceuticals, Inc. announced today that it is presenting two abstracts from studies of its lead clinical candidate, CXL-1020, at the American College of Cardiology's (ACC) 60th Annual Scientific Session & Expo in New Orleans, Louisiana. Preclinical results highlighted in the first abstract demonstrate CXL-1020's ability to work independently from other heart failure therapies, furthering important insights into the cellular mechanism of action of nitroxyl donors. Clinical results presented in the second abstract demonstrate, for the first time, CXL-1020's safety and tolerability in people who have stable congestive heart failure (CHF), a good predictor of safety in people with acute decompensated heart failure (ADHF).  

"Today's research findings provide additional support for the unique mechanism of CXL-1020 and for its strong safety profile and tolerability in patients with stable CHF," said Chris Kroeger, M.D., President and Chief Executive Officer.  "We are currently enrolling a Phase IIa clinical trial to further define safety, tolerability and dosing for CXL-1020 in patients with ADHF, bringing us closer to making this treatment a reality for the millions who suffer from this disease."  

Following are the details of the data presented at ACC Poster Sessions:

CXL-1020, a Novel HNO Donor, Decreases Myocardial Loading and Enhances Load-Independent Lusitropy and Inotropy via a Beta-AR/ACE Independent Mechanism. Monday, April 4, 2011; 1:45 p.m. – 4:45 p.m., Ernest N. Morial Convention Center, Hall F; Poster Board #21

In this preclinical study, Cardioxyl and QTest Labs researchers compared the hemodynamic profile of CXL-1020 with the vasodilator, sodium nitroprusside (SNP).  The results show that under conditions of matched reduction of systolic pressure, CXL-1020 and SNP increased stroke volume without incre
'/>"/>

SOURCE Cardioxyl Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIa Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Ohio , Jan. 15, 2014  A novel ... soon make it easy and painless for patients to ... treat a wide range of disorders, including cancer, blood ... An emerging biologic drugs market is expected to grow ... these drugs will require a new type of injector ...
(Date:1/14/2014)... Jan. 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), ... that it acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... The terms of the acquisition were not disclosed. ... company providing a wide range of sleep, mobility, and respiratory ... and Pittsburgh markets. Progressive was ...
(Date:1/14/2014)... , Jan. 14, 2014   Oligomerix, Inc. ... of disease modifying therapeutics for Alzheimer,s disease (AD) ... of its corporate headquarters to Valhalla, ... and expanded lease agreement for additional laboratory space ... which is focused on the development of small ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... 30 Wound Care,Innovations, LLC, a subsidiary of ... today that it will attend and exhibit at,the ... Boston. This,seminar is presented by HMP Communications, the ... and producers of the Symposium on,Advanced Wound Care. ...
... NIH; Findings could benefit,pregnant women worldwide, SEATTLE, ... and Human Development division of the National Institutes ... a $2.9 million grant,for a five-year research project ... known as preeclampsia and migraine., Dr. Williams ...
Cached Medicine Technology:Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R) 2Swedish in Seattle to Study Connections Between Preeclampsia and Migraine 2Swedish in Seattle to Study Connections Between Preeclampsia and Migraine 3
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... for Installation in United Kingdom, SUNNYVALE, Calif., ... a global leader in the field of radiosurgery,announced ... America (HCA), has purchased its seventh CyberKnife(R),Robotic Radiosurgery ... London,England. This marks HCA,s first non-U.S. CyberKnife System ...
... of heart disease, study finds , , THURSDAY, Oct. 4 (HealthDay ... abnormality in the heart,s left main artery should take special ... brothers and sisters of someone with such problems are 2.5 ... compared to the siblings of patients with heart disease not ...
... Oct 4 Anesiva, Inc.,(Nasdaq: ANSV ) ... for the,investment community to review the company,s launch ... injection system. The briefing will take place on ... Eastern Time in New York City. To,access the ...
... ... diabetes complication, ALEXANDRIA, Va., Oct. 4 Halloween can ... But for some, there is something that is much scarier ... diabetes complication for both men and women.,According to the American ...
... PA) responds to the president,s veto of the ... don,t add up. This President is willing to ... support $35 billion to insure 10 million,of our ... to their,well being. Today,s SCHIP veto proves the ...
... MILWAUKEE, Oct. 3 Could you actually be allergic ... in the workplace,you may suffer from occupational asthma. This ... allergens, chemicals,fumes, gases, dusts or other potentially harmful substances ... Allergy, Asthma & Immunology,(AAAAI). "We estimate that about ...
Cached Medicine News:Health News:Hospital Corporation of America Purchases Seventh CyberKnife(R) System 2Health News:Hospital Corporation of America Purchases Seventh CyberKnife(R) System 3Health News:Hospital Corporation of America Purchases Seventh CyberKnife(R) System 4Health News:Cardiac Artery Trouble Boosts Family Heart Risk 2Health News:Cardiac Artery Trouble Boosts Family Heart Risk 3Health News:Anesiva to Unveil Zingo(TM) Commercialization Plans 2Health News:Diabetes in the Bedroom: Scarier than Halloween? 2Health News:AAAAI: Asthma on the Job 2Health News:AAAAI: Asthma on the Job 3
... onboard rail clamps mount ... tables and stretchers. The ... need for lifting. Easy ... stable surface combined with ...
The DHS Basic Set is available with either self-tapping or non-self-tapping screws. Either instrument set provides complete instrumentation in one graphic case for use with the Universal Implant Set,...
... is a versatile, fully powered orthopaedic and ... traction facilities, a powered centre break and ... versatile too. ,<br.,In fact the RX600 is ... it is for traction procedures. The RX600 ...
... orthopedic trauma procedures. Part of the ... trauma table top provides a complete, ... positioning and provides for skin or ... hip pinnings; femur, supine or lateral ...
Medicine Products: